Viking Therapeutics (VKTX) Profit After Tax (2014 - 2026)
Viking Therapeutics (VKTX) posted Profit After Tax of -$128.3 million for Q2 2026, up 19.58% sequentially from -$159.6 million in Q1 2026, and down 95.72% YoY from -$3.0 billion in Q2 2025.
Viking Therapeutics (VKTX) Profit After Tax (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Profit After Tax for 13 years, with the latest figure at -$128.3 million in Q2 2026.
- Quarterly Profit After Tax fell 95.72% year-over-year to -$128.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$536.3 million (down 211.92% YoY) and the FY2025 annual result came in at -$359.6 million, down 225.87% from the prior year.
- Profit After Tax rose to -$128.3 million in Q2 2026 per VKTX's latest filing, from -$159.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$15.9 million in Q3 2022 and troughed at -$159.6 million in Q1 2026.
- A 5-year average of -$50.9 million and a median of -$24.8 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax dropped 10.68% in 2024, then plunged 340.2% in 2025.
- Over 5 years, Profit After Tax stood at -$18.9 million in 2022, then tumbled by 30.19% to -$24.6 million in 2023, then tumbled by 45.56% to -$35.8 million in 2024, then tumbled by 340.2% to -$157.7 million in 2025, then rose by 18.61% to -$128.3 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$128.3 million, -$159.6 million, and -$157.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | -128.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -128.32 Mn |
| Mar 31, 2026 | -159.56 Mn |
| Dec 31, 2025 | -157.66 Mn |
| Sep 30, 2025 | -90.79 Mn |
| Jun 30, 2025 | -65.56 Mn |
| Mar 31, 2025 | -45.63 Mn |
| Dec 31, 2024 | -35.82 Mn |
| Sep 30, 2024 | -24.94 Mn |
| Jun 30, 2024 | -22.92 Mn |
| Mar 31, 2024 | -28.57 Mn |
| Dec 31, 2023 | -24.61 Mn |
| Sep 30, 2023 | -22.53 Mn |
| Jun 30, 2023 | -19.65 Mn |
| Mar 31, 2023 | -19.53 Mn |
| Dec 31, 2022 | -18.90 Mn |
| Sep 30, 2022 | -15.89 Mn |
| Jun 30, 2022 | -17.67 Mn |
| Mar 31, 2022 | -16.97 Mn |
| Dec 31, 2021 | -12.74 Mn |
| Sep 30, 2021 | -13.24 Mn |